March 17, 2020 / 11:16 AM / 17 days ago

BRIEF-Regeneron Announces Important Advances In Novel Covid-19 Antibody Program

March 17 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON ANNOUNCES IMPORTANT ADVANCES IN NOVEL COVID-19 ANTIBODY PROGRAM

* REGENERON PHARMACEUTICALS INC - POTENTIAL TO ENTER HUMAN CLINICAL STUDIES BY EARLY SUMMER

* REGENERON PHARMACEUTICALS INC - REGENERON HAS IDENTIFIED HUNDREDS OF VIRUS-NEUTRALIZING ANTIBODIES

* REGENERON PHARMACEUTICALS INC - PLANS TO INITIATE LARGE-SCALE MANUFACTURING BY MID-APRIL WITH ANTIBODY COCKTAIL THERAPY

* REGENERON PHARMACEUTICALS - APPLYING VELOCIMAB TECHNOLOGY TO PREPARE MANUFACTURING-READY CELL LINES AS LEAD ANTIBODIES ARE SELECTED

* REGENERON PHARMACEUTICALS INC - WORKING TOWARD GOAL OF PRODUCING HUNDREDS OF THOUSANDS OF PROPHYLACTIC DOSES PER MONTH BY END OF SUMMER

* REGENERON PHARMACEUTICALS INC - WORKING TOWARD GOAL OF PRODUCING HUNDREDS OF THOUSANDS OF PROPHYLACTIC DOSES PER MONTH BY END OF SUMMER

* REGENERON - ISOLATED ANTIBODIES FROM HUMANS WHO HAVE RECOVERED FROM COVID-19, IN ORDER TO MAXIMIZE POOL OF POTENTIALLY POTENT ANTIBODIES

* REGENERON - HOPES TO HAVE SMALLER QUANTITIES OF PROPHYLACTIC DOSES AVAILABLE FOR INITIAL CLINICAL TESTING AT BEGINNING OF SUMMER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below